Login
$DRIO
$1.15 -$0.11 (8.73%) Live

Company Executives

Management Team

From the 10-K annual report
Officer Age In this role Source
Erez Raphael Also a director
Chief Executive Officer and Director
51 Not stated
Zvi Ben David
Chief Financial Officer, Treasurer and Secretary
64 Since 2015
11 years
Chen Franco-Yehuda
Chief Financial Officer
Title from the Form 4 dated Sep 24, 2026
Not stated Not stated
Lara Ann Sherman
Chief Operating Officer
Title from the Form 3 dated Sep 24, 2026
Not stated Not stated

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Dec 22, 2025 · updated by the 8-Ks of Apr 13, 2026, Sep 4, 2026, and Nov 6, 2026

Directors
7
serving now
Independent
4 of 4
stated in the proxy; 3 not stated
Average tenure
8.8 years
from year joined
CEO also chairs the board
No
Yoav Shaked and John R. Palumbo
Director Age On board Independent Committees Other public boards 2024 pay Source
Yoav Shaked
54 Not stated Independent
Audit Committee Compensation Committee Nominating and Corporate Governance Committee
Endospan Ltd., Vibrant Ltd., G&G Biotechnology Ltd., Orasis Pharmaceuticals, Ltd. $168,700
John R. Palumbo Joined Apr 10, 2026
- - - - - -
Erez Raphael
51 2014
11 years
Not stated None stated None stated Paid as CEO
Dennis Matheis
65 2020
5 years
Independent
Audit Committee Nominating and Corporate Governance Committee · Chair
None stated $135,100
Hila Karah
57 2014
11 years
Independent
Compensation Committee
Intec Pharma, Cyren Ltd $135,100
Dennis M. McGrath
68 2013
12 years
Independent
Audit Committee · Chair Compensation Committee · Chair
Citius Oncology, Inc., Citius Pharmaceuticals, Inc. $204,400
Adam Stern
61 2020
5 years
Not stated None stated Aerami Therapeutics Holdings, Matinas BioPharma Holdings, Inc., Adgero Biopharmaceuticals Holdings, Hydrofarm Holdings Group, Inc. $130,100

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

We could not read related-party transactions reliably

Rather than show a list that might be incomplete, we show nothing. They are in the proxy filed Dec 22, 2025, in its related person transactions section.

Read them in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support